Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhonghua Gas Holdings Ltd
HKEX:8246
|
HK |
|
Bounty Oil and Gas NL
ASX:BUY
|
AU |
|
Ibersol SGPS SA
LSE:0KJ7
|
PT |
|
K
|
Kuehne und Nagel International AG
XBER:KNIA
|
CH |
|
FNB Corp
NYSE:FNB
|
US |
|
Tobu Railway Co Ltd
TSE:9001
|
JP |
|
J
|
Jiangxi Firstar Panel Technology Co Ltd
SZSE:300256
|
CN |
Prescient Therapeutics Ltd
EPS (Diluted)
Prescient Therapeutics Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Prescient Therapeutics Ltd
ASX:PTX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Mesoblast Ltd
ASX:MSB
|
EPS (Diluted)
$0
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
EPS (Diluted)
$2
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's EPS (Diluted)?
EPS (Diluted)
-0
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's EPS (Diluted) amounts to -0 AUD.
What is Prescient Therapeutics Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
10%
Over the last year, the EPS (Diluted) growth was 0%.